Tag: investor

Alm. Brand A/S share buy-back program

Press Release

Nedenfor følger informasjon om transaksjoner foretatt under andre transje av Equinor ASAs (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO) tilbakekjøpsprogram for 2025.

Please see below information about transactions made under the second tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 125,600 IPC common shares (ISIN: CA46016U1084) during the period of June 2 to 6, 2025 under IPC’s normal course issuer bid / share repurchase program (NCIB).

Progress on share buyback programme

STOCKHOLM and NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NASDAQ: VIRT), a global leader in trading and execution services, and Limina, a leading provider of cloud-native Investment Management Solutions, are proud to announce a strategic collaboration around Virtu’s TradeOPS platform.

Press Release

Bigbank AS (registry code 10183757, address Riia tn 2, Tartu, 51004) (“Bigbank”) hereby announces a public offering (the “Offering”) of its unsecured subordinated bonds. The Offering is conducted pursuant to the prospectus (the “Prospectus”) prepared by Bigbank and registered by the Estonian Financial Supervision and Resolution Authority (“EFSA”) on 9 June 2025. The Prospectus, which provides further details, has been disclosed on the date of this announcement on the websites of Bigbank and the EFSA. 

BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited (“RenaissThera”), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield “Hits”. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies.